Advertisement

Topics

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

2014-08-27 03:56:00 | BioPortfolio

Summary

RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer.

PURPOSE: Screening trial to determine the significance of CA 125 levels in detecting ovarian cancer in participants who have a high genetic risk of developing ovarian cancer.

Description

OBJECTIVES:

- Determine the feasibility of prospective ovarian cancer screening studies within the Cancer Genetics Network and other NCI ovarian programs for participants who are at high genetic risk for developing ovarian cancer.

- Identify the logistical issues of screening these participants and their solutions within this framework.

- Establish normal ranges and distributions of CA 125 values over time within and between high-risk participants, with subclassification by pre- or post-menopausal status, estrogen-replacement therapy usage, and prior prophylactic oophorectomy.

- Estimate the specificity and positive predictive value of the "risk of ovarian cancer algorithm" (ROCA) suitable for designing a definitive trial of screening for ovarian cancer in high-risk participants.

- Establish a longitudinal serum and plasma biorepository for retrospective evaluation of other promising biomarkers with special relevance to inherited ovarian and breast cancer risk.

OUTLINE: This is a multicenter study. Participants with 1 or 2 ovaries are assigned to group A, whereas participants with prior prophylactic bilateral oophorectomy are assigned to group B (closed to accrual as of 10/18/04).

At baseline, participants who are not eligible by BRCA mutation criteria or family history criteria undergo BRCAPRO evaluation. Participants in both groups complete a questionnaire requesting demographic information and a personal and family health history at baseline and a questionnaire requesting hospitalization or cancer diagnosis information after each blood test. Participants in both groups also complete health status questionnaires once every 3 months for 6 months-7 years. Participants undergo blood draws for measurement of CA 125 levels once every 3 months for 6 months-7 years. For each CA 125 measurement, the risk of ovarian cancer algorithm (ROCA) is calculated.

Group A (1 or 2 ovaries at baseline):

- Participants are assigned to 1 of 2 subgroups based on ROCA.

- Subgroup A1: Participants with normal-risk for ovarian cancer (ROCA less than 1%) continue CA 125 screening as above.

- Subgroup A2: Participants with intermediate-risk for ovarian cancer (ROCA more than 1% but less than 10%) or elevated-risk for ovarian cancer (ROCA more than 10%) undergo transvaginal sonography (TVS). Participants with elevated-risk undergo an additional blood draw for a confirmatory CA 125 level prior to TVS. Participants with normal TVS continue CA 125 screening as above. Participants with abnormal TVS are referred to a gynecologic oncologist who decides whether standard clinical intervention for potential ovarian cancer is needed. Participants who are not referred for standard clinical intervention continue CA 125 screening as above. Participants who are referred for standard clinical intervention, have at least 1 ovary remaining, and are found to have no malignancy continue CA 125 screening as above. Participants who are referred for standard clinical intervention, are found to have no malignancy, and then undergo prophylactic bilateral oophorectomy proceed to CA 125 screening as in group B below. Participants who are referred for standard clinical intervention and are found to have malignancy are taken off study.

Group B (no ovaries at baseline) (closed to accrual as of 10/18/04):

- Participants are assigned to 1 of 2 subgroups based on ROCA.

- Subgroup B1: Participants with normal-risk for ovarian cancer (ROCA less than 5%) continue CA 125 screening as above.

- Subgroup B2: Participants with elevated-risk for ovarian cancer (ROCA more than 5%) undergo an additional blood draw for a confirmatory CA 125 level and are then referred to a gynecologic oncologist who decides whether standard clinical intervention for potential ovarian cancer is needed. Participants who are not referred for standard clinical intervention continue CA 125 screening as above. Participants who are referred for standard clinical intervention and are not found to have malignancy continue CA 125 screening as above. Participants who are referred for standard clinical intervention and are found to have malignancy are taken off study.

Patients are followed for clinical diagnosis for 1 additional year.

PROJECTED ACCRUAL: Approximately 2,430 participants will be accrued for this study within 12 months.

Study Design

Primary Purpose: Screening

Conditions

Ovarian Cancer

Intervention

screening questionnaire administration, study of high risk factors

Location

Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange
California
United States
92868

Status

Recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:56:00-0400

Clinical Trials [5766 Associated Clinical Trials listed on BioPortfolio]

Screening Study of Surgery and CA 125 Levels in Participants at Increased Genetic Risk of Ovarian Cancer

RATIONALE: Surgery to remove the fallopian tubes and ovaries may decrease the risk of ovarian cancer and may improve quality of life in women who are at increased genetic risk. Monitoring ...

Study of Individuals and Families at High Risk for Breast or Ovarian Cancer

RATIONALE: Studying individuals and families at high risk for breast or ovarian cancer may help in identifying the genes involved in the development of breast and ovarian cancer and help t...

CA-125 in Screening Patients at High Risk for Ovarian Cancer

RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help doctors detect cancer early and plan more effective treatment. ...

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

RATIONALE: Gathering information about genetic factors in women with an increased risk of ovarian cancer over time may help doctors learn more about the disease and find better methods of ...

Screening Individuals and Families at High Risk for Hematologic Cancers

RATIONALE: Evaluating genetic and environmental factors in individuals and families at high risk of developing hematologic cancer may help doctors plan more effective treatments. PURPOSE:...

PubMed Articles [52905 Associated PubMed Articles listed on BioPortfolio]

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.

Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carr...

Substance use among students in Thailand.

This study explored substance use prevalence, level of risk, and associated factors, especially related to binge drinking. A cross-sectional study was conducted among 306 students using questionnaires...

Multiple risk factors prediction models for high risk population of colorectal cancer.

Colorectal cancer is caused by the interaction of genetic and environment factors. Domestic and foreign scholars have attempted to develop several colorectal cancer risk prediction models, in order to...

Nausea and vomiting of pregnancy: A study with pregnancy-unique quantification of emesis questionnaire.

Nausea and vomiting of pregnancy (NVP) is frequent, affecting up to 70-85% of pregnant women. However, severity of NVP especially in clinical practice is often uncertainly assessed and thus both under...

A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.

When some individuals are screen-detected before the beginning of the study, but otherwise would have been diagnosed symptomatically during the study, this results in different case-ascertainment prob...

Medical and Biotech [MESH] Definitions

Administration of a medication to at-risk individuals in a population without individual diagnosis. It is often used in order to treat, control, and/or prevent spread of often endemic DISEASE OUTBREAKS such as NEGLECTED DISEASES in high disease burden areas.

Factors that can cause or prevent the outcome of interest, are not intermediate variables, and are not associated with the factor(s) under investigation. They give rise to situations in which the effects of two processes are not separated, or the contribution of causal factors cannot be separated, or the measure of the effect of exposure or risk is distorted because of its association with other factors influencing the outcome of the study.

The relating of causes to the effects they produce. Causes are termed necessary when they must always precede an effect and sufficient when they initiate or produce an effect. Any of several factors may be associated with the potential disease causation or outcome, including predisposing factors, enabling factors, precipitating factors, reinforcing factors, and risk factors.

Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.

Self report questionnaire which yields 16 scores on personality traits, such as reserved vs. outgoing, humble vs. assertive, etc.

More From BioPortfolio on "Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial